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Tatjana Banovic,1 Kelli P. A. MacDonald,1 Kate A. Markey,1 Edward S. Morris,1
Rachel D. Kuns,1 Antiopi Varelias,1 Geoffrey R. Hill1,2Donor treatment with granulocyle-colony stimulating factor (G-CSF) is known to modulate immune func-
tion, characterized by the generation of regulatory myelogenous and T cell populations and Th2 differenti-
ation. Recently, these effects have been shown to be enhanced by pegylation of the G-CSF molecule, which
also improves graft-versus-leukemia (GVL) via activation of invariant natural killer (iNK) T cells. We have
compared G-CSF bound to a single PEG molecule (monopeg-G-CSF) as used clinically to a G-CSF molecule
bound to multiple PEG molecules (multipeg–G-CSF) in major histocompatibility complex (MHC) disparate
and matched models of graft-versus-host disease (GVHD) and GVL. We demonstrate that multipeg-G-CSF
induces greater levels of progenitor cell, myelogenous, and iNKT cell expansion than monopeg-G-CSF, while
inducing similar protection from GVHD. Despite this, multipeg-G-CSF enhanced CTL function in vivo and
improved iNKT cell-dependent leukemia clearance. Thus, GVL and GVHD can be further separated after
allogeneic stem cell transplantation by mobilization with a multiple-pegylated G-CSF molecule.
Biol Blood Marrow Transplant 15: 126-130 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Graft-versus-host disease, Graft-versus-leukemiaINTRODUCTION
Graft-versus-host disease (GVHD) remains a major
complication following allogeneichemopoietic stemcell
transplantation (SCT), with the resultant multiorgan
damage and immune deficiency significantly impairing
overall transplant survival. The use of recombinant hu-
man granulocyte colony-stimulating factor (G-CSF)
mobilized stem cell grafts has led to rapid immune and
hemopoietic reconstitution, reduced treatment-related
mortality (TRM), and improved leukemia eradication
in high-risk patients [1]. T cells from donors treated
with G-CSF have a reduced capacity to induce GVHD
on a per-cell basis relative to those from control treated
donors [2] andG-CSFmay also reduceGVHD through
effects on multiple cells, including invariant natural
killer T (iNKT) cells (reviewed in [3,4]). iNKT cells
have inhibitory or stimulatory properties, depending
on subsets, anatomic location, and the stage of an im-1The Queensland Institute of Medical Research, 300
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6/j.bbmt.2008.11.019mune response on which they act [5-9]. We have
previously demonstrated that the clinically available
mono–pegylated form of G-CSF (Neulasta) is superior
to standard G-CSF for the prevention of GVHD,
whereas paradoxically improving graft-versus-leukemia
(GVL) via iNKT-dependent effects [10,11]. There are
potential biologic advantages to cytokine formulations
with multiple pegylation conjugates; however, in some
cases suchmodifications can diminish or eliminate func-
tion [12]. We, therefore, investigated whether multiple
pegylation (at 2 to 4 sites) of the G-CSF molecule re-
sulted in enhanced immune modulation and improved
transplant outcome.
MATERIALS AND METHODS
Mice
FemaleB6 (H-2b,CD45.21 andPTPRCa,CD45.11),
B10.D2 (H-2d), DBA/2 (H-2d), and B6D2F1 (H-2b/d,
CD45.21) mice were purchased from the Animal
Resources Centre (Perth, Western Australia, Aus-
tralia). Ja182/2 B6 (H-2b, CD45.21) mice were sup-
plied by Mark Smyth (Peter MacCullum Cancer
Centre, Melbourne, Australia). Mice were housed in
sterilized microisolator cages and received acidified
autoclaved water (pH 2.5) post-transplantation.
Cytokine Treatment
Recombinant human G-CSF linked to a single
PEGmolecule (monopeg-G-CSF, orNeulasta, Amgen,
Biol Blood Marrow Transplant 15:126-130, 2009 127Multipegylated G-CSFThousand Oaks, CA) or multiply pegylated (multipeg-
G-CSF, Amgen) was given subcutaneously at 3 mg/ani-
mal on day26. Donor spleens were harvested on day 0.
Stem Cell Transplantation
Mice were transplanted as described previously
[10,11,13]. Briefly, on day –1, B6D2F1 or DBA/2
mice received TBI (1100 cGy or 1000 cGy, respec-
tively), split into 2 doses. B6 (107) or B10.D2
(2  107) donor splenocytes were equilibrated (to de-
liver the same T cell doses) or T cell depleted, and in-
jected intravenously on day 0. T cell depletion was
undertaken as previously described [13]. Transplanted
mice were monitored daily, and those with GVHD
clinical scores [14] of 6 or greater were sacrificed and
the date of death registered as the next day in accor-
dance with institutional animal ethics committee
guidelines.SD01SP2.002
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Figure 1. Comparative effects of monopeg-G-CSF and multipeg-G-CSF on do
of 3 mg of monopeg-G-CSF or multipeg-G-CSF at day26. Spleens were subse
cidated per spleen (n5 5 or 6 per group). (B) Representative plots of lineage2
CSF or multipeg-G-CSF. (C) Percentage and absolute numbers of lineagenegc-k
treatment (n 5 8 per group). Dashed line represents average numbers in naı¨vLeukemia Challenge
Themastocytoma cell line P815 (H-2d, CD45.21),
which derived from DBA/2 mice, was injected intrave-
nously into recipients on day 0 of transplantation. Sur-
vival and clinical scores were monitored daily and the
cause of death established as GVHD or leukemia as
previously described [10]. In vivo imaging was per-
formed using the IVIS Imaging System (Xenogen,
CA) and light emission is presented as photons/sec-
ond/cm2/sr.Flow Cytometry and In Vivo Cytotoxicity Index
Flow cytometry, including the determination of
lineage negative (Mac-1, CD19, Gr-1, CD4, CD8,
NK1.1, and TER119), c-kit, and Sca-1-positive cells
was undertaken as previously described [10,15]. In
vivo CTL assays were performed as previously=0.0006
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nor splenic phenotype. (A) B6 donors received 1 subcutaneous injection
quently phenotyped on day 0, and total numbers of each cell lineage elu-
Sca-11c-kit1 cells in the spleen 6 days after treatment with monopeg-G-
it1Sca-11 cells in spleen following monopeg-G-CSF or multipeg-G-CSF
e animals (n 5 3). Data combined from 2 replicate experiments.
128 Biol Blood Marrow Transplant 15:126-130, 2009T. Banovic et al.described by determining the clearance of adoptively
transferred host versus donor splenocytes 12 days after
SCT [10,16].Statistical Analysis
Survival curves were plotted using Kaplan-Meier
estimates and compared by log-rank analysis. P\.05
was considered statistically significant. Data presented
as mean 6 SEM.RESULTS AND DISCUSSION
Multipeg-G-CSF Results in Greater Levels of
Progenitor, Myelogenous, and iNKT Cell
Expansion, But Similar Protection from GVHD
Phase I clinical studies in normal donors have dem-
onstrated that 12mgof the singularly pegylated-G-CSF
(Neulasta, equivalent to100-200mg/kg) results in robust
stemcellmobilizationwith an acceptable side effect pro-
file [17]. Thus, monopeg-G-CSF or multipeg-G-CSF
was administered to donormice at a clinically achievable
dose (3 mg/dose, equivalent to 150 mg/kg), and 6 days
later spleens were phenotyped. As demonstrated in
Figure 1A, the expansion of myelogenous cells (mono-
cytes and granulocytes) and iNKTcells was significantly
greater in recipients of multipeg-G–CSF. The absolute
numbers of other lineage positive cells were similar. To
determine effects on progenitor cell content, lineageA
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Figure 2. Comparative effects of monopeg-G-CSF and multipeg-G-CSF on G
in irradiated B6D2F1 recipients (1100 cGy, day21) transplanted at day 0 with 1
G-CSF allo, n 5 24) or multipeg-G-CSF (multipeg-G-CSF allo, n 5 24), equilib
transplants from saline-treated allogeneic B6 donors (control allo, n5 8) or syn
were transplanted with T cell-depleted (TCD) allogeneic grafts from multip
pooled from 3 experiments. P values shown compare peg-G-CSF allo groups. (
nocytes from allogeneic B6 or syngeneic B6D2F1 monopeg-G-CSF (monopeg
(multipeg-G–CSF allo, n 5 16, multipeg-G-CSF syn, n 5 6) treated donors. A
in Materials and Methods. Data represented as mean 6 SE from 3 experimennegative, c-kit1, and sca-1 1 stem cells were quantified
within the spleen. As shown in Figure 1B and C, multi-
peg-G-CSF significantly increased the frequency (and
number) of progenitor cells in this peripheral site,
whereas those in the marrow were mildly reduced
(data not shown).
When splenic grafts (equilibrated to T cell dose)
were transplanted into major histocompatibility com-
plex (MHC)disparate, lethally irradiatedB6D2F1 recip-
ients, both monopeg-G-CSF and multi–peg-G-CSF
provided significant protection fromGVHD.However,
significant differences between monopeg-G-CSF
and multipeg-G-CSF were not apparent (Figure 2A),
although, in each of 3 experiments, multipeg-G-CSF
appeared marginally superior. Because we have previ-
ously demonstrated the activation of donor iNKT cells
by monopeg-G-CSF with subsequent enhancement of
donor CTL function [10], we next determined in vivo
CTL generation in SCT recipients 12 days after trans-
plant. As shown in Figure 2B, donor treatment with
multipeg-G-CSF resulted in significantly greater CTL
activity after SCT than monopeg-G-CSF.
Treatment with Multipeg-G-CSF Improves
Overall Survival (OS) and iNKT- Dependent
GVL Activity
To study the effect of treatment with multipeg-
G-CSF on GVL effects, we utilized an MHCmatched
(B10.D2/ DBA/2) SCT model of GVHD directed
to multiple minor histocompatibility antigens, in0.0
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VHD and CTL activity after SCT. (A) Survival by Kaplan-Meier analysis
07 splenocytes from B6 donors treated with monopeg-G-CSF (monopeg-
rated to deliver equal T cell doses. Control B6D2F1 recipients received
geneic B6D2F1 donors (control syn, n5 9). Additional control recipients
eg-G-CSF-treated B6 donors (multipeg-G-CSF TCD, n 5 4). Results
B) Irradiated allogeneic B6D2F1 recipients were transplanted with sple-
–G-CSF allo, n 5 15, monopeg-G-CSF syn, n 5 3) or multipeg-G-CSF
t day 112 the in vivo cytotoxicity index was determined as described
ts.
Biol Blood Marrow Transplant 15:126-130, 2009 129Multipegylated G-CSFwhich recipients also received host-type luciferase ex-
pressing leukemia (P815) at the time of transplant.
The recipients of multipeg-G-CSF mobilized grafts
demonstrated significantly improved OS (Figure 3A),
relative to recipients of monopeg-G-CSF mobilized
grafts because of enhanced leukemia eradication
(Figure 3B) that was confirmed by biophotonic imag-
ing post-SCT (Figure 3C and D). To confirm that
this was indeed related to effects on iNKT cells, wild-
type (WT) and iNKT deficient (Ja182/2) B6 donors
weremobilizedwithmultipeg-G-CSF and grafts trans-
planted into irradiated B6D2F1 recipients in the pres-
ence of host-type leukemia and GVL monitored
thereafter. As shown in Figure 3E, recipients of
T cell-depleted grafts died by day 12 of leukemia,
whereas over 60% of recipients of multipeg-G-CSF
mobilized T cell-replete grafts survived. In contrast,
recipients of multipeg-G-CSF mobilized Ja182/2A
D
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Figure 3. Multipeg-G-CSF mediates GVL effects in an NKT cell-dependent fa
recipients transplanted with splenocytes from allogeneic B10.D2 (2  107 cell
(n 5 27 each), equilibrated to deliver equal T cell doses. Non-GVHD control
T cell depleted (n5 15). Leukemia was induced in all recipients by coinjection of
from 3 experiments. P values shown compare peg –G-CSF allo groups. (B) Leu
P values shown compare peg-G-CSF allo groups. (C) Luminescence (photons
recipients shown in (A). Results are mean6 SE from 3 experiments, *P\.05, m
tonic imaging of leukemia development at days110-14 in allogeneic (T cell reple
B10.D2 grafts or multi–peg-G-CSF TCD grafts. All TCD recipients developed
mortality by Kaplan-Meier analysis in B6D2F1 recipients transplanted with
multipeg-G-CSF allo, n 5 20), NKT cell deficient Ja182/2 (Ja 182/2, multip
TCD, n5 10) B6 donors in conjunction with 5  104 host-type P815 leukemiagrafts all developed progressive leukemiawith amedian
survival of only 23 days.
Consistent with this, the leukemic burden as deter-
mined by biophotonic imaging was higher in recipi-
ents of Ja 82/2 multipeg-G-CSF mobilized grafts
relative to WT multpeg-G-CSF mobilized grafts
(luminescence (105 photons/second/cm2/sr, respec-
tively) at day 18: 7.1 6 4.0 versus 3.7 6 1.6,
P 5 .028). Furthermore, GVHD mortality in recipi-
ents of WT multipeg-G-CSF and Ja 82/2 multipeg-
G-CSF grafts was 29% and 0%, respectively
(P 5 .16), confirming that GVHD was not increased
in the absence of donor NKT cells. This is consistent
with our previous data demonstrating that donor
NKTcells exacerbatedGVHD followingmobilization
with monopeg-G- CSF.10
The ability of pegylated-G-CSF to modulate the
immune system to greater levels than standard G-CSFC
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/second/cm2/sr) over time as a determinant of leukemia burden in the
ono–peg-G-CSF allo versus multipeg-G-CSF allo. (D) Xenogen biopho-
te;1T) DBA/2 recipients of monopeg-G-CSF or multipeg-G-CSF-treated
leukemia on day 10 and required sacrifice prior to day 14. (E) Leukemic
splenocytes from multipeg-G-CSF-treated allogeneic wild-type (WT
eg-G-CSF allo, n 5 20), or T cell-depleted WT (WT multipeg-G-CSF
cells. P values shown compare peg-G-CSF allo groups.
130 Biol Blood Marrow Transplant 15:126-130, 2009T. Banovic et al.is likely to be the result of the greatly increased half life
(from hours to days) in conjunction with an apparent
enhancement of receptor-ligand binding and traffick-
ing at the cell surface [3,18]. This appears to allow the
molecule to invoke effects in cell subsets that are other-
wise not demonstrable following standard G-CSF ad-
ministration, namely, iNKT cells (reviewed in [3]).
The activation of donor CD4negCD8neg iNKT cells,
thereafter, improves CTL priming via effects on host
APC [3,10]. The additional increase in biologic activity
by multiple-pegylation is likely to be imparted by en-
hancement of the same mechanisms. However, it is im-
portant to note that these effects cannot be reproduced
by mobilization with escalating doses of standard
G-CSF [10]. These data suggest that mobilizing stem
cells with multipegylated versions of G-CSF may be
advantageous in the allogeneic SCT setting to further
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